HHS submits peptide drug policy for White House review
The proposed policy could allow the FDA to exercise enforcement discretion on certain peptide medications.
AI-assisted coverage comparison, editor-supervised · How this was made
(Image courtesy Unsplash)
Photograph: WND (embedded from source)
What this story says
- The Department of Health and Human Services (HHS) has submitted an action plan for peptide medication to the Office of Management and Budget (OMB) for review.
- The American Academy of Peptide Medicine (AAPM) is the listed requestor for the policy, which aims to provide interim access to certain peptide drugs.
- FDA staff scientists have previously raised concerns about the safety and efficacy of some peptide drugs, stating they may cause harm.
- The proposed policy could grant the FDA "enforcement discretion," allowing it to decide whether to enforce current restrictions on these drugs.
Who covered it
Percentages are shares of the 9 outlets carrying a published leaning rating. 2 of the 11 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
42/100
Craft
57/100
Hype
41/100
11 sources · methodology
Thin on the left so far
None of the 9 outlets with a published leaning rating that ran this story are rated left.
This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.
The Department of Health and Human Services (HHS) has submitted a policy plan concerning peptide medications to the Office of Management and Budget (OMB) for review. The American Academy of Peptide Medicine (AAPM) is identified as the requestor for this policy, titled "Interim Access Policy for Compounding Certain Peptides." This submission follows the FDA's Pharmacy Compounding Advisory Committee's vote in July to approve six out of seven peptides considered.
FDA staff scientists have previously expressed concerns that certain peptide drugs have not undergone sufficient study to confirm their safety and effectiveness, and may pose risks. The proposed policy could allow the FDA to exercise "enforcement discretion," meaning the agency could choose not to enforce existing restrictions on some of these peptide drugs.
Disagreement on policy's aim
The WND report states that the policy is a "priority plan to put peptides in pharmacies" and quotes AAPM chair Lee Rosebush saying the posting is a "welcome signal that the process is moving forward" and that they "urge HHS and FDA to place these substances on the interim bulk drug substances lists, which would give patients a safe, legitimate source and help eliminate the black and gray markets." Ars Technica reports that the policy would "ease access to unproven peptide drugs" and that FDA staff scientists found the drugs "have not been sufficiently studied to establish safety and efficacy and may cause harms."
What the coverage left out
None of the right-rated reports mention the concerns raised by FDA staff scientists regarding the safety and efficacy of certain peptide drugs, nor do they include statements from advocacy groups like the Center for Science in the Public Interest that warned of potential harm to consumers. The centre-rated report from Ars Technica included these details.
Still developing. We have re-checked which outlets are covering this 5 times, most recently on 18 Oct 2026, 05:15, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
0 rated outlets
No outlet rated left has run this story so far. We are still checking, and will say plainly if that does not change.
Centre
1 rated outlet
- Ars Technica led on the potential for the policy to ease access to unproven peptide drugs, despite concerns from FDA staff scientists about their safety and efficacy. The report noted that the policy could give the FDA "enforcement discretion" on certain peptide drugs, allowing it to choose not to enforce current restrictions. It also highlighted that many prominent figures in the Make America Healthy Again movement, associated with Health Secretary Robert F. Kennedy Jr., sell peptide products. The outlet quoted Pete Lurie, president of the Center for Science in the Public Interest, calling the committee's recommendations potentially harmful to consumers.
Right
8 rated outlets
- Reports from right-rated outlets, including WND and The Daily Caller, focused on the submission of the "Interim Access Policy for Compounding Certain Peptides" to the OMB as a priority plan to get peptides into pharmacies. These reports quoted AAPM chair Lee Rosebush expressing encouragement and urging the placement of substances on interim bulk drug lists for safe, legitimate access and to combat black and gray markets. WND also noted that Robert F. Kennedy Jr. reaffirmed his dedication to getting peptides approved for patients in an April post on his X account.
Questions about this coverage
- How did the left and right cover HHS submits peptide drug policy for White House review?
- Of the 9 outlets on this story carrying a published leaning rating, 0% are rated left, 11% are rated centre, 89% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 11. The sections above set out what each side emphasised, in its own terms.
- Is HHS submits peptide drug policy for White House review left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 9 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of HHS submits peptide drug policy for White House review biased?
- HHS submits peptide drug policy for White House review is one event reported by 11 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which side is not reporting HHS submits peptide drug policy for White House review?
- When we first saw this story, outlets rated left had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
- Which outlets covered HHS submits peptide drug policy for White House review?
- 11 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What is the proposed policy regarding peptide medications?
- The Department of Health and Human Services has submitted an "Interim Access Policy for Compounding Certain Peptides" to the Office of Management and Budget for review. This policy could allow the FDA to exercise "enforcement discretion," meaning it might choose not to enforce current restrictions on certain peptide drugs.
- Who requested this policy?
- The American Academy of Peptide Medicine (AAPM) is listed as the requestor for the proposed policy. AAPM is a nonprofit academic society dedicated to advancing the responsible clinical use of peptide therapies.
- What concerns have been raised about these peptide drugs?
- FDA staff scientists have indicated that certain peptide drugs have not been sufficiently studied to establish their safety and efficacy and may cause harms. Advocacy groups have also warned that unproven peptides could put consumers at risk of serious injury.
Read it at the source
11 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
0No outlet in this group ran the story.
Centre
1Right
8- RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House * WorldNetDaily * by Libby Bandelin, Daily Caller News Foundation (opens OpsLens in a new tab)
- RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House * WorldNetDaily * by Libby Bandelin, Daily Caller News Foundation (opens WND in a new tab)
- RFK Jr.’s Priority Plan To Put Peptides In Pharmacies Pushed To White House (opens modernity.news in a new tab)
modernity.news — is modernity.news biased? Our profile of this outlet
- RFK Jr.'s Priority Plan to Put Peptides in Pharmacies Pushed to White House (opens 🔔 The Liberty Daily in a new tab)
🔔 The Liberty Daily — is 🔔 The Liberty Daily biased? Our profile of this outlet
- RFK Jr’s Priority Plan To Put Peptides In Pharmacies Pushed To White House (opens The Daily Caller in a new tab)
The Daily Caller — is The Daily Caller biased? Our profile of this outlet
- RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House - The Daily Bo Snerdley (opens thedailybs.com in a new tab)
thedailybs.com — is thedailybs.com biased? Our profile of this outlet
- HHS Proposes Letting Pharmacies Make Peptides (opens 105.9 FM and AM 630—Where Washington Comes To Talk | WMAL-AF… in a new tab)
- HHS proposes letting pharmacies make peptides (opens Washington Times in a new tab)
Washington Times — is Washington Times biased? Our profile of this outlet
Not rated
2- RFK Jr. Urges FDA to Ignore Unproven Peptides, According to Report (opens themondonews.com in a new tab)
themondonews.com — is themondonews.com biased? Our profile of this outlet
- FDA considers interim access for compounded peptides; Enspryng's label expansion (opens endpoints.news in a new tab)
endpoints.news — is endpoints.news biased? Our profile of this outlet
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
